Arkema SA (OTCMKTS:ARKAY – Get Free Report) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 418 shares, a drop of 75.8% from the July 15th total of 1,729 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 2,816 shares, the days-to-cover ratio is presently 0.1 days.
Arkema Trading Down 0.0%
OTCMKTS:ARKAY opened at $71.81 on Thursday. Arkema has a 52-week low of $56.28 and a 52-week high of $79.36. The company has a quick ratio of 1.64, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The stock has a fifty day simple moving average of $65.98 and a 200-day simple moving average of $67.85. The company has a market capitalization of $5.46 billion, a PE ratio of 247.62 and a beta of 0.85.
Arkema (OTCMKTS:ARKAY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The basic materials company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.12. Arkema had a net margin of 0.67% and a return on equity of 4.27%. The firm had revenue of $2.79 billion for the quarter, compared to analysts’ expectations of $2.86 billion. On average, equities research analysts expect that Arkema will post 3.67 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Research Report on ARKAY
About Arkema
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total’s chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema’s operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
See Also
- Five stocks we like better than Arkema
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Arkema Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arkema and related companies with MarketBeat.com's FREE daily email newsletter.
